enter
new
age
molecular
diagnost
test
infecti
diseas
follow
nearli
centuri
tradit
culturebas
method
requir
growth
organ
analysi
phenotyp
properti
molecular
test
proven
faster
often
time
equal
sensit
tradit
counterpart
mani
instanc
longer
need
wait
day
week
organ
replic
instead
identif
organ
avail
minut
hour
possibl
due
technolog
focus
genet
signatur
individu
organ
molecular
diagnost
undergon
complet
renov
past
two
decad
invent
polymeras
chain
reaction
pcr
becam
possibl
replic
nucleic
acid
small
amount
sampl
patient
provid
enough
genet
materi
examin
pcr
technolog
depend
numer
cycl
heat
cool
laboratorian
manual
transfer
sampl
hot
cool
water
bath
sever
hour
autom
instrument
thermocycl
minim
handson
time
addit
discoveri
taq
polymeras
autom
process
even
allow
largescal
use
pcr
technolog
first
step
molecular
assay
extract
nucleic
acid
patient
specimen
mani
instrument
avail
carri
rel
simpl
costeffect
manner
howev
step
take
time
manual
labor
need
load
unload
instrument
therefor
newer
assay
util
board
extract
addit
equip
handon
step
requir
nucleic
acid
extract
two
stage
process
lysi
organ
purif
nucleic
acid
lysi
done
via
pressur
heat
chemic
sonic
mechan
method
bead
beat
purif
done
immobil
nucleic
acid
bind
materi
wash
sever
time
elut
nucleic
acid
water
buffer
use
pcr
must
way
examin
whether
amplicon
made
mani
sever
year
gel
electrophoresi
mainstay
part
process
labori
time
consum
use
potenti
danger
chemic
newer
technolog
allow
detect
quantit
amplifi
dna
amplif
exampl
intercal
fluoresc
dye
newli
creat
strand
fluoresc
intens
correl
dna
concentr
measur
real
time
addit
method
confirm
specif
amplif
process
sometim
util
melt
curv
analysi
assess
temperatur
newli
creat
doublestrand
dna
dissoci
melt
fairli
specif
target
dna
target
assay
molecular
method
past
requir
three
distinct
geograph
area
within
laboratori
prepcr
extract
purif
pcr
amplif
postpcr
analysi
gel
electrophoresi
melt
curv
laboratori
wish
partak
method
lot
space
accommod
reason
minim
risk
contamin
amplifi
nucleic
acid
plagu
pcr
technolog
updat
technolog
develop
even
extrem
care
amplicon
one
reaction
could
contamin
reaction
littl
nucleic
acid
need
begin
small
amount
anoth
patient
sampl
anoth
assay
could
seriou
disast
newer
technolog
offer
complet
close
reaction
sampl
never
open
never
touch
human
hand
amplif
detect
quantit
nucleic
acid
occur
within
close
contain
substanti
minim
possibl
contamin
rapid
identif
organ
extraordinarili
benefici
patient
know
caus
organ
alon
sometim
enough
treatment
often
depend
antimicrobi
particular
strain
organ
respond
thank
numer
molecular
assay
detect
gene
confer
resist
variou
antimicrobi
although
pcr
commonli
use
technolog
system
method
sequencespecif
nucleic
acid
amplif
also
use
altern
approach
refer
sequencespecif
isotherm
amplif
protocol
requir
chang
reaction
temperatur
common
advantag
isotherm
techniqu
extrem
fast
requir
thermocycl
transcriptionmedi
amplif
tma
nick
enzym
amplif
reaction
near
two
exampl
isotherm
amplif
protocol
describ
detail
pertain
specif
assay
advanc
pcr
technolog
diagnost
method
becom
smaller
simpler
phrase
sampletoresult
describ
technolog
entail
onboard
nucleic
acid
extract
amplif
analysi
assay
requir
minim
handson
time
oftentim
reagent
includ
control
store
directli
individu
cartridg
entir
close
process
substanti
reduc
risk
contamin
instrument
small
shoebox
highervolum
instrument
floormodel
allow
lab
size
partak
new
technolog
review
limit
truli
sampletoresult
assay
therefor
includ
molecular
infecti
diseas
test
examin
use
technolog
infecti
diseas
nearli
organ
system
gastrointestin
genitourinari
central
nervou
system
cn
respiratori
summari
manufactur
provid
tabl
explor
clinic
implic
ask
import
question
benefit
patient
perhap
robust
area
molecular
infecti
diseas
test
field
upper
respiratori
infect
numer
manufactur
instrument
avail
test
sever
differ
organ
influenza
viru
pcr
mani
advantag
convent
diagnost
techniqu
includ
cultur
rapid
antigen
test
recov
influenza
cultur
take
sever
day
far
long
wait
begin
therapi
rapid
antigen
test
although
fast
easi
perform
plagu
low
sensit
direct
fluoresc
antibodi
dfa
test
although
rel
fast
depend
upon
collect
cell
sampl
requir
fluoresc
microscop
nucleic
acid
test
perform
time
frame
meaning
patient
manag
highli
sensit
specif
mani
manufactur
offer
assay
requir
minim
handson
time
minim
expertis
basic
molecular
diagnost
molecular
test
unlik
antigen
test
influenza
consid
diagnost
confirmatori
test
perform
first
assay
discuss
cepheid
xpert
flu
run
genexpert
instrument
genexpert
system
run
xpert
assay
cartridg
necessari
reagent
control
includ
cartridg
see
review
numer
assay
offer
use
instrument
cartridg
fit
instrument
instrument
avail
vari
size
singlecartridg
system
way
system
hold
cartridg
one
time
genexpert
infin
system
hold
either
cartridg
equip
robot
load
system
reduc
handson
time
highvolum
laboratori
modul
within
system
oper
individu
system
randomaccess
run
mani
differ
assay
lab
would
like
time
eg
influenza
assay
run
one
time
time
later
clostridium
difficil
assay
run
modul
next
door
etc
therefor
system
extrem
flexibl
laboratori
size
sampl
pipet
sampl
area
cartridg
cartridg
load
individu
modul
within
system
simpli
open
drawer
insert
cartridg
similar
inkjet
printer
load
ink
cartridg
within
instrument
plunger
descend
cartridg
forc
valv
bodi
rotat
multipl
plung
rotat
occur
isol
organ
onto
solid
membran
add
reagent
solut
lysi
occur
via
sonic
addit
rotat
valv
occur
add
reagent
forc
sampl
reaction
chamber
jut
cartridg
similar
shark
fin
follow
one
round
thermocycl
solut
pull
back
cartridg
addit
reagent
ad
solut
forc
back
reaction
chamber
undergo
anoth
round
thermocycl
accompani
color
detect
complet
realtim
pcr
reaction
xpert
flu
assay
detect
differenti
influenza
influenza
influenza
b
nasopharyng
swab
nasal
aspirateswash
less
minut
overal
report
sensit
upward
compar
molecular
method
howev
studi
report
lower
sensit
influenza
b
separ
xpert
assay
xpert
flursv
xc
detect
differenti
influenza
influenza
b
respiratori
syncyti
viru
approxim
one
hour
compar
molecular
method
report
sensit
assay
greater
influenza
influenza
b
rsv
focu
simplexa
flu
ab
rsv
direct
assay
consist
flat
disk
resembl
compact
disk
integr
cycler
instrument
eight
well
disk
cover
adhes
prior
begin
test
adhes
cover
partial
pull
back
expos
well
one
singleus
reaction
mix
vial
per
sampl
allow
thaw
room
temperatur
storag
fixedvolum
pipett
use
inocul
reaction
mix
patient
sampl
appropri
section
reaction
well
well
recov
adhes
disk
load
onto
integr
cycler
run
take
approxim
hour
complet
compar
laboratorydevelop
revers
transcript
pcr
one
studi
report
sensit
influenza
b
rsv
respect
anoth
commonli
use
system
upper
respiratori
infect
filmarray
respiratori
panel
rp
first
approv
us
fda
may
subsequ
version
sinc
approv
filmarray
instrument
randomaccess
singlemodul
system
reaction
occur
within
one
dispos
pouch
multipl
instrument
may
connect
one
laptop
filmarray
pouch
contain
freezedri
reagent
discret
blister
step
within
multiplex
nest
pcr
process
melt
curv
analysi
complet
blister
pouch
entir
close
includ
wast
pouch
dispos
singl
use
user
add
provid
hydrat
solut
pouch
draw
solut
syring
place
syring
port
pouch
pouch
draw
requir
volum
vacuum
measur
necessari
user
patient
sampl
mix
sampl
buffer
similarli
inocul
pouch
instrument
close
assay
begun
handson
time
requir
instrument
drive
procedur
set
protocol
use
mechan
forc
thermal
chang
optic
cell
patient
sampl
disrupt
mechan
bead
beat
first
blister
nucleic
acid
extract
multipl
wash
step
wast
push
first
blister
subsequ
blister
first
stage
pcr
take
place
largevolum
highli
multiplex
reaction
amplicon
dilut
fluoresc
dna
bind
dye
ad
solut
distribut
among
well
array
contain
specif
primer
target
second
nest
singleplex
stage
pcr
occur
triplic
array
follow
dna
melt
curv
analysi
pouch
contain
two
control
associ
softwar
interpret
analysi
qualit
result
display
laptop
monitor
current
version
filmarray
rp
contain
target
includ
numer
strain
influenza
parainfluenza
coronaviru
rsv
human
metapneumoviru
rhinovirusenteroviru
adenoviru
three
bacteri
target
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
see
tabl
report
sensit
rang
variou
organ
panel
comparison
method
previou
version
assay
report
low
sensit
adenoviru
appear
substanti
improv
current
version
couturi
et
al
report
sensit
analyt
except
influenza
b
adenoviru
one
studi
report
sensit
bordetella
pertussi
compar
focu
analytespecif
reagent
high
sensit
also
report
offlabel
use
sputum
nose
throat
swab
lower
respiratori
specimen
assay
take
approxim
hour
minim
handson
time
nanospher
verigen
respiratori
viral
plu
rv
anoth
rel
larg
panel
see
tabl
verigen
system
contain
two
instrument
processor
analyz
unlik
complet
selfcontain
cartridg
pouch
use
system
verigen
dispos
consist
cartridg
patient
sampl
inocul
separ
reagent
pack
load
onto
analyz
pcr
occur
follow
hybrid
target
dna
onto
captur
oligonucleotid
microarray
addit
gold
nanoparticl
probe
user
transfer
cartridg
analyz
reader
analysi
hybrid
dna
occur
qualit
result
report
although
sensit
specif
reportedli
studi
compar
filmarray
rp
verigen
rv
show
high
rate
invalid
test
verigen
compar
filmarray
studi
also
show
sensit
filmarray
verigen
influenza
assay
compar
anoth
molecular
method
prodess
butt
et
al
perform
workflow
analysi
determin
total
handson
time
includ
set
step
report
result
minut
total
turnaround
time
tat
minut
verigen
comparison
studi
found
filmarray
rp
handson
time
minut
tat
minut
attribut
longer
handson
time
verigen
rv
panel
thaw
frozen
reagent
return
instrument
move
cartridg
analyz
reader
one
potenti
limit
rapid
molecular
test
cost
howev
fast
tat
new
assay
implic
patient
care
outcom
could
lead
save
overal
healthcar
cost
studi
compar
influenza
season
use
focu
simplexa
assay
previou
influenza
season
use
tradit
realtim
pcr
tat
hour
show
patient
test
neg
influenza
convent
assay
season
given
median
durat
day
oseltamivir
patient
test
neg
focu
assay
season
given
median
day
treatment
roger
et
al
compar
filmarray
rp
convent
method
patient
less
year
old
admit
uncompl
respiratori
ill
mostli
via
emerg
depart
averag
tat
hour
filmarray
rp
hour
convent
method
differ
whether
antibiot
prescrib
cover
possibl
bacteri
infect
durat
antibiot
shorter
filmarray
group
obtain
result
within
hour
test
posit
length
hospit
stay
time
isol
also
lower
patient
posit
filmarray
rp
compar
patient
posit
test
use
convent
method
author
found
use
filmarray
rp
cost
total
less
per
patient
convent
method
outcom
factor
focu
studi
found
despit
higher
laboratori
cost
per
test
overal
cost
focu
assay
season
less
per
patient
addit
studi
compar
filmarray
rp
laboratorydevelop
batch
multiplex
rtpcr
assay
luminex
xtag
rvp
shown
rp
like
give
diagnosi
pathogen
detect
may
especi
import
immunocompromis
patient
could
downstream
effect
decreas
hospit
length
stay
decreas
unnecessari
antimicrobi
treatment
decreas
diagnost
test
decreas
readmiss
rate
unnecessari
outpati
encount
butt
et
al
report
list
price
per
test
filmarray
rp
cost
per
report
analyt
found
verigen
rv
cost
per
test
cost
per
report
analyt
minim
handson
time
fast
tat
lack
analysi
interpret
requir
perform
test
locat
special
microbiolog
molecular
laboratori
may
necessari
xu
et
al
report
success
experi
assay
core
lab
report
high
rate
oseltamivir
prescript
dose
given
emerg
depart
time
manner
patient
posit
influenza
anoth
potenti
use
molecular
respiratori
test
pointofcar
poc
poc
assay
obtain
clinic
laboratori
improv
amend
clia
waiver
substanti
decreas
regulatori
requir
associ
perform
test
nonlab
set
instanc
emerg
depart
physician
offic
aler
fda
approv
june
grant
clia
waiver
januari
although
assay
clia
waiv
substanti
complex
waiv
test
current
market
eg
rapid
antigen
test
betahcg
test
system
compris
instrument
perform
one
test
time
kit
contain
sampl
receiv
test
base
transfer
cartridg
instrument
screen
direct
user
follow
step
procedur
sampl
receiv
test
base
insert
aler
instrument
user
wait
minut
sampl
nasopharyng
swab
insert
sampl
receiv
contain
elut
buffer
transfer
cartridg
use
pipett
sampl
test
base
contain
two
reaction
tube
contain
lyophil
reagent
lid
instrument
close
result
given
approxim
minut
instrument
use
isotherm
nucleic
acid
amplif
technolog
call
near
employ
stranddisplac
dna
polymeras
initi
nick
creat
nick
enzym
rapidli
produc
mani
short
nucleic
acid
target
sequenc
requir
lengthi
complex
thermocycl
dna
purif
near
technolog
deliv
pcrcalib
result
significantli
faster
gener
abund
amplifi
product
trillion
time
short
amount
time
enabl
molecular
detect
minut
also
compens
suboptim
sampl
collect
manufactur
packag
insert
claim
sensit
specif
influenza
influenza
b
respect
compar
viral
cultur
bell
et
al
found
sensit
aler
influenza
b
assay
compar
viral
cell
cultur
aler
also
claim
posit
percent
agreement
neg
percent
agreement
pcr
influenza
influenza
b
respect
recent
studi
shown
sensit
compar
pcr
howev
one
studi
report
specif
influenza
influenza
b
compar
genexpert
cepheid
pcr
discrep
resolv
xtag
rvp
luminex
final
two
recal
two
differ
lot
differ
reason
issu
within
first
year
clia
waiver
issu
unlik
mani
molecular
respiratori
test
aler
use
nasal
swab
instead
nasopharyng
swab
potenti
allow
collect
substanti
comfort
patient
roch
coba
liat
lab
tube
influenza
b
assay
recent
septemb
grant
clia
waiver
system
compos
singlemodul
instrument
wandlik
cartridg
instrument
screen
prompt
user
process
sampl
nasopharyng
swab
univers
transport
media
ad
sampl
tube
use
includ
nonprecis
pipett
sampl
tube
insert
instrument
reaction
occur
within
minut
sampl
tube
divid
sever
seal
segment
contain
necessari
reagent
sampl
move
one
segment
next
compress
instrument
undergo
step
requir
realtim
revers
transcriptas
pcr
within
close
liat
tube
binnick
et
al
report
sensit
influenza
influenza
b
specif
compar
focu
simplexa
flu
ab
rsv
assay
describ
studi
show
clinic
impact
poc
test
need
tuberculosi
caus
mycobacterium
tuberculosi
tb
second
common
infecti
caus
death
worldwid
human
immunodefici
viru
syndrom
hiv
organ
first
infect
lung
dissemin
organ
system
estim
million
new
case
global
case
occur
lowincom
countri
million
peopl
die
diseas
rapid
highli
accur
sensit
diagnost
test
global
prioriti
control
tuberculosi
tb
control
strategi
effort
imped
slow
complex
diagnost
method
acidfast
bacilli
afb
smear
test
wide
use
detect
tb
year
howev
detect
mycobacteria
tb
henc
low
specif
addit
mani
patient
neg
afb
smear
subsequ
posit
cultur
therefor
neg
smear
exclud
tb
diseas
convent
culturebas
method
take
week
mycobacteria
grow
addit
week
antimicrobi
suscept
test
characterist
sampletoresult
molecular
test
tb
numer
advantag
convent
smear
cultur
even
area
low
preval
xpert
mtbrif
assay
run
genexpert
system
describ
necessari
reagent
control
includ
dispos
cartridg
assay
detect
tb
resist
rifampin
sputum
specimen
hour
minim
handson
time
use
realtim
pcr
assay
amplifi
tbspecif
sequenc
addit
mutat
within
rpob
gene
detect
confer
resist
rifampin
rifampin
resist
often
correl
isoniazid
resist
therefor
presenc
rpob
generesist
mutat
sometim
earli
marker
multidrugresist
mdr
tuberculosi
requir
aggress
approach
treatment
infect
control
review
publish
data
paper
larg
multicentr
studi
well
unpublish
singlecent
studi
late
review
result
singlecent
evalu
studi
show
assay
sensit
rang
smearposit
patient
smearneg
patient
compar
cultur
specif
report
rang
rifampinresist
detect
sensit
specif
result
control
clinic
valid
trial
suspect
tb
individu
show
sensit
singl
direct
xpert
test
smearnegativecultureposit
three
smearneg
sampl
test
xpert
specif
sensit
specif
rifampin
resist
detect
respect
februari
publish
addit
evid
includ
systemat
review
total
studi
involv
particip
review
show
sensit
pool
specif
compar
cultur
xpert
mtbrif
use
initi
diagnost
test
replac
smear
microscopi
xpert
mtbrif
yield
pool
sensit
pool
specif
use
addon
test
follow
neg
smear
microscopi
use
xpert
mtbrif
smearposit
cultureposit
tb
show
pool
sensit
addit
xpert
mtbrif
achiev
pool
sensit
pool
specif
detect
rifampin
resist
perform
xpert
mtbrif
assay
user
add
bactericid
buffer
sputum
transfer
defin
volum
cartridg
reduc
viabil
tuberculosi
sputum
least
unit
minut
incub
therefor
elimin
requir
biosafeti
cabinet
xpert
mtbrif
use
vari
temperatur
humid
condit
requir
minim
personnel
train
reason
assay
could
use
region
nonspeci
laboratori
potenti
outsid
laboratori
set
develop
countri
novel
molecular
test
limit
need
convent
cultur
drug
resist
test
elimin
xpert
mtbrif
technolog
test
still
requir
monitor
respons
treatment
detect
resist
antibiot
rifampin
neg
xpert
mtbrif
exclud
diagnosi
tb
cdc
report
tb
case
unit
state
report
neg
cultur
may
also
neg
nucleic
acid
amplif
test
may
due
low
bacteri
load
presenc
inhibit
substanc
sampl
oper
aspect
one
limit
assay
need
uninterrupt
electr
power
suppli
well
annual
valid
system
may
problemat
underdevelop
area
although
test
expens
smear
culturebas
method
rapid
high
sensit
specif
make
appeal
use
altern
convent
serial
sputum
microscopi
implement
assay
may
lead
budgetari
increas
laboratori
short
term
compar
smear
microscopi
howev
rapid
result
xpert
mtbrif
assay
may
contribut
substanti
cost
save
avoid
unnecessari
treatment
infect
control
practic
airborn
respiratori
isol
millman
et
al
suggest
routin
use
xpert
mtbrif
could
contribut
decreas
cost
per
inpati
admiss
would
turn
save
approxim
per
year
mediums
urban
public
hospit
decemb
endors
xpertmtb
rif
use
endem
countri
strongli
recommend
test
use
initi
diagnost
test
individu
suspect
mdr
tb
hivassoci
tb
sever
agenc
includ
bill
melinda
gate
foundat
form
agreement
cepheid
provid
discount
cost
elig
develop
countri
initi
cost
fourmodul
instrument
laptop
approxim
cost
per
cartridg
rapid
molecular
test
shown
promis
impact
tb
control
strategi
worldwid
one
studi
estim
implement
nucleic
acid
amplif
test
global
reduc
tb
incid
rate
earlier
diagnosi
earlier
initi
treatment
earlier
infect
control
strategi
appropri
implement
test
substanti
benefit
patient
healthcar
provid
hospit
public
health
system
studi
need
perform
futur
applic
xpert
mtbrif
particularli
pediatr
popul
extrapulmonari
tuberculosi
use
assay
monitor
respons
treatment
conclus
studi
shown
sampletoresult
molecular
test
respiratori
pathogen
rapid
simpl
posit
impact
patient
care
patient
present
sign
symptom
could
consist
infect
cn
often
undergo
lumbar
punctur
numer
test
perform
cerebrospin
fluid
csf
cn
infect
caus
virus
bacteria
fungi
rare
parasit
enteroviru
common
caus
asept
mening
etiolog
found
diseas
selflimit
specif
antivir
therapi
avail
howev
viral
mening
difficult
differenti
bacteri
mening
caus
cn
diseas
patient
often
admit
treat
empir
condit
firm
diagnosi
made
therefor
would
reason
assum
rapid
diagnosi
enteroviru
would
substanti
decreas
length
stay
antimicrobi
administr
hospit
cost
seen
studi
use
cepheid
xpert
ev
assay
giulieri
colleagu
compar
patient
asept
mening
diagnos
via
xpert
ev
assay
tat
collect
result
hour
convent
homebrew
pcr
tat
hour
patient
diagnosi
found
patient
diagnosi
confirm
genexpert
significantli
shorter
durat
empir
antibiot
fewer
patient
receiv
empir
acyclovir
patient
averag
length
stay
day
compar
day
day
patient
group
convent
pcr
diagnosi
respect
assay
observ
sensit
specif
test
take
hour
run
minim
handson
time
use
csf
categor
clia
moder
complex
hsv
type
type
caus
enceph
predomin
postneonat
period
patient
present
sign
symptom
could
consist
infect
place
acyclovir
soon
diagnosi
consid
untreat
mortal
approxim
pcr
vastli
improv
patient
manag
outcom
compar
tradit
culturebas
serolog
method
empir
antivir
interfer
pcr
may
cultur
serolog
take
week
confirm
acut
infect
limit
valu
care
patient
final
pcr
substanti
less
invas
brain
biopsi
one
time
consid
gold
standard
diagnosi
hsv
infect
cn
hsv
pcr
perform
use
moder
complex
focu
simplexa
hsv
direct
assay
integr
cycler
describ
filmarray
meningitisenceph
panel
fda
approv
octob
assay
perform
similar
rp
describ
use
unprocess
csf
take
minut
handson
time
result
avail
hour
panel
test
follow
organ
escherichia
coli
haemophilu
influenza
listeria
monocytogen
neisseria
meningitidi
streptococcu
agalactia
streptococcu
pneumonia
cytomegaloviru
enteroviru
human
parechoviru
varicella
zoster
viru
cryptococcu
neoforman
current
peerreview
publish
studi
state
perform
clinic
implic
assay
sinc
identif
organ
csf
eg
human
parechoviru
past
limit
import
studi
new
diagnost
techniqu
impact
patient
care
infecti
diarrhea
affect
million
peopl
year
around
globe
high
morbid
mortal
substanti
impact
healthcar
system
report
estim
children
death
per
day
due
infecti
gastroenter
us
nation
bill
patient
suffer
gastrointestin
infect
billion
rapid
accur
detect
gi
pathogen
import
appropri
therapi
proper
infect
control
strategi
clinic
present
infecti
gastroenter
much
help
term
specifi
etiolog
diarrhea
primari
symptom
regardless
caus
agent
make
challeng
clinician
decid
test
order
also
mani
agent
diagnost
test
avail
current
case
infecti
diarrhea
etiolog
agent
remain
unidentifi
result
improp
therapi
convent
bacteri
cultur
antigen
detect
microscopi
ova
parasit
viral
cultur
singleplex
realtim
pcr
assay
use
identifi
variou
organ
method
time
consum
labor
intens
test
limit
number
organ
despit
fact
caus
agent
sometim
indistinguish
clinic
convent
method
requir
clinician
select
appropri
test
util
shotgun
approach
order
numer
test
one
time
moreov
result
test
may
avail
sever
day
prolong
tat
make
test
less
attract
particularli
respect
patient
manag
etiolog
diagnosi
infecti
diarrhea
extrem
benefici
patient
manag
infect
control
public
health
strategi
result
interest
util
multiplex
molecular
assay
identif
caus
agent
infecti
diarrhea
increas
multiplex
molecular
assay
use
pcr
simultan
detect
identifi
multipl
gastrointestin
pathogen
nucleic
acid
extract
stool
specimen
two
fdaapprov
commerci
avail
multiplex
sampletoresult
assay
filmarray
gi
panel
verigen
enter
pathogen
ep
panel
filmarray
gi
panel
includ
target
bacteri
five
viral
four
parasit
within
singl
pouch
see
tabl
verigen
ep
panel
abil
identifi
nine
target
five
bacteri
two
viral
two
toxin
see
tabl
filmarray
gi
panel
work
almost
ident
rp
describ
khare
et
al
demonstr
major
target
repres
filmarray
gi
panel
show
high
sensit
specif
buss
et
al
studi
case
report
filmarray
gi
panel
sensitivityposit
predict
valu
target
plesiomona
shigelloid
salmonella
spp
yersinia
enterocolitica
enterotoxigen
escherichia
coli
etec
shiga
toxinproduc
e
coli
stec
e
coli
cryptosporidium
spp
cyclospora
cayetanensi
giardia
lamblia
astroviru
rotaviru
sapoviru
target
filmarray
sensitivityposit
predict
valu
filmarray
specificityneg
predict
valu
target
convent
method
identifi
least
two
pathogen
sampl
filmarray
show
overal
rate
mix
infect
buss
et
al
detect
multipl
pathogen
specimen
verigen
ep
panel
also
fda
approv
includ
target
five
bacteria
two
virus
two
toxin
see
tabl
time
write
peerreview
publish
studi
demonstr
sensit
specif
workflow
analysi
assay
manufactur
report
handson
time
minut
runtim
hour
limit
regard
gastrointestin
panel
first
detect
larg
number
possibl
pathogen
combin
asymptomat
infect
target
pathogen
uncommon
especi
pediatr
popul
interpret
posit
result
identifi
main
culprit
symptom
challeng
second
limit
convent
bacteri
cultur
may
still
requir
determin
suscept
antibiot
epidemiolog
track
possibl
outbreak
eg
salmonella
serotyp
howev
given
rapid
obtain
posit
pcr
result
may
still
possibl
cultur
organ
specimen
one
major
limit
panel
may
cost
cost
filmarray
gi
panel
per
sampl
estim
less
minut
total
handson
technologist
time
setup
report
result
cost
run
filmarray
gi
panel
detect
identifi
pathogen
compar
averag
three
test
order
convent
method
per
specimen
barney
hopper
nelsonmil
c
et
al
unpublish
data
gi
panel
signific
infect
control
implic
place
patient
unsuspect
gi
pathogen
appropri
isol
remov
patient
neg
gi
panel
unnecessari
isol
filmarray
gi
panel
potenti
lead
logic
approach
patient
isol
would
minim
risk
nosocomi
infect
also
significantli
reduc
associ
cost
increas
patient
satisfact
rand
et
al
save
inpati
residu
sampl
origin
submit
test
neg
clostridium
difficil
andor
rotaviru
test
filmarray
gi
panel
studi
sampl
least
one
infecti
agent
detect
patient
never
place
isol
addit
identifi
patient
could
remov
isol
base
neg
filmarray
gi
panel
studi
indic
numer
pathogen
current
underdiagnos
may
inappropri
use
underus
isol
interest
studi
conduct
nebraska
medic
center
cyclosporiasi
outbreak
occur
iowa
nebraska
institut
carri
unrel
research
studi
filmarray
time
filmarray
gi
panel
detect
cyclospora
prior
earli
phase
outbreak
specimen
went
unidentifi
clinic
laboratori
cyclosporiasi
clinic
suspect
therefor
modifi
acidfast
stain
initi
order
first
posit
cyclospora
specimen
use
filmarray
gi
panel
collect
week
prior
first
report
posit
case
nebraska
indic
filmarray
util
screen
tool
outbreak
would
like
detect
earlier
similar
studi
shigellosi
outbreak
rhode
island
filmarray
gi
panel
quicker
convent
cultur
also
detect
case
shigellaeiec
enteroinvas
e
coli
compar
cultur
anoth
advantag
filmarray
gi
panel
use
close
system
minim
risk
contamin
routin
use
panel
potenti
allow
costeffect
time
detect
multipl
pathogen
could
lead
improv
public
health
cost
save
due
optim
use
laboratori
resourc
reduc
transmiss
outbreak
addit
area
cost
save
may
includ
prevent
repeat
healthcar
encount
etiolog
agent
would
known
soon
first
visit
studi
regard
cost
analysi
warrant
toxigen
clostridium
difficil
main
caus
healthcar
antibioticassoci
diarrhea
caus
rang
mild
sever
diseas
pseudomembran
coliti
toxic
megacolon
perfor
colon
sepsi
rare
death
c
difficil
larg
impact
health
care
least
us
billion
spent
per
year
detect
c
difficil
quickli
accur
import
appropri
antibiot
treatment
proper
infect
control
strategi
especi
outbreak
varieti
test
current
avail
detect
c
difficil
stool
sampl
test
includ
cultur
antigen
detect
toxigen
cultur
enzym
immunoassay
molecular
test
stool
cultur
sensit
test
avail
howev
labori
slow
tat
hour
determin
presenc
toxin
antigen
detect
test
rapid
test
hour
use
latex
agglutin
immunochromatographi
detect
presenc
c
difficil
antigen
test
nonspecif
pathogen
strain
organ
produc
toxin
therefor
use
combin
specif
test
lesssensit
test
requir
three
separ
collect
stool
sampl
lead
old
order
adag
c
diff
time
tissu
cultur
cytotox
assay
c
difficil
detect
toxin
b
consid
diagnost
gold
standard
mani
year
howev
assay
expens
slow
tat
hour
requir
substanti
technic
expertis
provid
specif
sensit
result
c
difficil
infect
howev
consid
less
sensit
pcr
toxigen
cultur
detect
organ
patient
diarrhea
enzym
immunoassay
detect
toxin
toxin
b
b
assay
inexpens
simpl
therefor
commonli
use
howev
rel
insensit
institut
employ
two
threestep
algorithm
diagnost
method
assay
enzym
glutam
dehydrogenas
molecular
test
util
pcr
detect
gene
encod
toxin
b
high
sensit
specif
fast
tat
cepheid
offer
two
fdaapprov
test
xpert
c
difficil
xpert
c
difficileepi
differenti
epidem
strain
north
american
profil
assay
perform
directli
stool
sampl
genexpert
system
nearli
ident
xpert
assay
describ
strain
implic
hospit
outbreak
verigen
c
difficil
test
abil
detect
toxin
toxin
b
gene
also
identifi
strain
c
difficil
shed
fece
therefor
spore
transfer
surfac
devic
materi
becom
contamin
fece
cdc
recommend
place
patient
privat
room
minim
transmiss
one
major
associ
cost
c
difficil
infect
length
hospit
stay
slow
tat
avail
test
attribut
longer
stay
perhap
unnecessari
isol
rapid
molecular
test
higher
sensit
specif
compar
rapid
test
one
sampl
requir
faster
tat
lead
earlier
detect
reduc
repeat
test
ultim
shorter
hospit
stay
unnecessari
isol
mani
institut
place
patient
contact
isol
c
difficil
suspect
often
done
flag
patient
pend
order
c
difficil
test
therefor
may
stay
isol
c
difficil
test
neg
approach
longer
c
difficil
test
take
longer
patient
may
stay
isol
may
may
need
isol
impli
extra
cost
hospit
patient
also
lead
patient
dissatisfact
studi
publish
societi
health
care
epidemiolog
america
shea
found
patient
place
contact
isol
like
report
perceiv
care
problem
twice
much
patient
contact
isol
limit
c
difficil
molecular
pcr
assay
metaanalysi
onlin
data
report
despit
high
sensit
specif
pcr
c
difficil
accuraci
assay
depend
c
difficil
preval
c
difficil
preval
test
popul
posit
predict
valu
possibl
lead
overtreat
unnecessari
isol
hand
c
difficil
preval
ppv
therefor
pcr
might
best
diagnost
test
patient
popul
low
preval
limit
molecular
assay
specif
detect
gene
encod
toxin
toxin
may
result
posit
result
asymptomat
c
difficil
carrier
patient
henc
institut
institut
algorithm
use
pcr
toxin
eia
order
increas
posit
predict
valu
addit
asymptomat
colon
toxigen
c
difficil
common
children
year
old
healthi
neonat
make
interpret
posit
result
complic
similar
filmarray
gi
panel
rapid
molecular
test
c
difficil
allow
costeffect
time
detect
organ
optim
use
laboratori
resourc
reduc
transmiss
outbreak
substanti
impact
patient
manag
satisfact
public
health
despit
benefit
molecular
test
diagnosi
c
difficil
continu
challeng
optim
diagnost
method
remain
difficult
achiev
limit
test
detect
asymptomat
carrier
taken
account
interpret
posit
result
diagnosi
treatment
sexual
transmit
infect
sti
import
complic
seriou
includ
pelvic
inflammatori
diseas
advers
neonat
outcom
associ
pregnanc
dissemin
infect
increas
risk
acquir
hiv
diagnosi
difficult
mani
infect
asymptomat
howev
asymptomat
infect
still
transmit
sexual
partner
addit
sign
symptom
nonspecif
easili
confus
genitourinari
diseas
diagnost
techniqu
rapid
highli
sensit
specif
increas
rate
treatment
time
treatment
partner
notif
reduc
overal
transmiss
preval
commun
convent
method
field
includ
cultur
laboratorydevelop
molecular
assay
serolog
immunochromatograph
poc
test
latter
routin
use
due
poor
perform
center
diseas
control
prevent
cdc
recommend
nucleic
acid
amplificationbas
test
chlamydia
trachomati
ct
neisseria
gonorrhoea
ng
cultur
except
explor
cdc
also
recommend
molecular
test
trichomona
vaginali
trichomona
flagel
protozoan
parasit
caus
vagin
women
urethr
men
although
often
asymptomat
cepheid
offer
xpert
ctng
assay
genexpert
platform
describ
result
avail
minut
assay
consid
moder
complex
approv
specimen
includ
patientcollect
vagin
swab
endocerv
swab
male
femal
urin
sensit
specif
ct
ng
report
high
sensit
specif
depend
analyt
specimen
type
comparison
method
test
perform
well
poc
set
one
studi
report
asymptomat
mostli
men
sex
men
msm
patient
test
onsit
sexual
health
clinic
london
receiv
treatment
day
test
compar
averag
day
histor
match
control
test
via
convent
method
offsit
hospitalbas
laboratori
popul
patient
posit
anoth
studi
involv
staff
perform
assay
remot
commun
australia
delay
test
via
convent
labbas
method
notif
patient
lead
averag
time
treatment
day
staff
given
train
session
regard
use
assay
instrument
end
studi
period
report
genexpert
easi
use
feasibl
remot
set
proof
concept
studi
result
genexpert
use
patient
care
perhap
futur
assay
becom
cliawaiv
use
poc
set
routin
holog
genprob
panther
oper
differ
previous
describ
sampletoresult
molecular
system
sampl
initi
load
follow
continuousfe
randomaccess
avail
sampl
process
hour
first
result
avail
hour
reagent
control
load
separ
usual
per
day
time
control
valid
hour
aptima
assay
util
hpv
ctng
trichomona
detect
simultan
sampl
assay
employ
transcriptionmedi
amplif
reflex
hpv
genotyp
type
occur
hpv
detect
approv
sampl
assay
includ
ctng
clinician
patient
selfcollect
vagin
swab
femal
endocerv
swab
male
urethr
swab
male
urin
thinprep
test
vial
trichomona
cliniciancollect
endocerv
vagin
swab
preservcyt
liquid
pap
specimen
hpv
thinprep
vial
although
femal
urin
fda
approv
panther
studi
shown
good
perform
detect
ctng
common
specimen
type
although
system
consid
highcomplex
fda
ratnam
et
al
found
system
lowest
overal
handson
time
includ
oper
mainten
step
compar
four
molecular
ct
assay
panther
use
tma
techniqu
contrast
pcr
method
involv
rna
transcript
via
rna
polymeras
dna
synthesi
via
revers
transcriptas
produc
rna
amplicon
target
nucleic
acid
either
dna
rna
tma
advantag
compar
pcr
exampl
isotherm
requir
lengthi
complex
thermal
cycl
tma
produc
rna
rather
dna
amplicon
rna
labil
laboratori
environ
reduc
possibl
carryov
contamin
lastli
tma
produc
copi
per
cycl
contrast
pcr
produc
two
copi
per
cycl
result
billionfold
increas
dna
rna
copi
within
minut
one
potenti
drawback
rel
recent
advanc
nucleic
acidbas
test
diagnosi
ng
lack
isol
perform
suscept
test
penicillin
tetracyclin
fluoroquinolon
longer
recommend
treatment
ng
widespread
resist
antibiot
therefor
suscept
test
necessari
initi
antibiot
select
howev
cdc
recommend
cultur
suscept
test
patient
demonstr
treatment
failur
also
suscept
test
necessari
survey
circul
isol
monitor
emerg
resist
anoth
limit
sti
molecular
test
potenti
area
futur
growth
lack
fdaapprov
test
ocular
rectal
pharyng
specimen
trachoma
caus
chlamydia
infect
eye
lead
caus
prevent
blind
worldwid
occur
mainli
resourcepoor
set
infect
seen
even
prophylact
treatment
presenc
infect
alway
correl
well
physic
find
one
studi
collect
ocular
sampl
tanzania
test
us
laboratori
genexpert
ctng
assay
achiev
sensit
specif
compar
anoth
molecular
assay
roch
amplicor
ctng
subsequ
studi
research
collect
two
swab
eye
children
year
old
one
swab
test
xpert
ctng
assay
field
tanzania
swab
sent
us
test
roch
amplicor
ctng
test
total
sampl
avail
analysi
xpert
assay
found
sensit
specif
sampl
obtain
result
genexpert
due
insuffici
sampl
n
materi
sampl
n
loss
electr
n
mani
gonococc
chlamydi
rectal
oropharyng
infect
asymptomat
cdc
recommend
certain
popul
msm
undergo
routin
genit
extragenit
screen
howev
fdaapprov
nucleic
acid
amplif
test
avail
rectal
oropharyng
sourc
laboratori
must
perform
valid
wish
test
sampl
site
goldenberg
et
al
test
rectal
swab
xpert
ctng
genexpert
aptima
assay
holog
genprob
tigri
platform
found
genexpert
sensit
specif
ct
ng
respect
howev
discrep
analys
perform
sampl
agre
two
assay
possibl
sensit
specif
higher
aptima
assay
deliv
falseposit
neg
result
interestingli
rectal
swab
sampl
requir
dilut
avoid
invalid
result
hsv
often
caus
genit
oral
sti
establish
latenc
primari
infect
reactiv
caus
recurr
local
diseas
extragenit
complic
occur
includ
dissemin
diseas
mening
proctiti
vertic
transmiss
mother
infant
occur
deliveri
make
diagnosi
activ
diseas
import
pregnanc
focu
hsv
direct
kit
recent
august
approv
genit
swab
sampl
addit
csf
see
accord
packag
insert
sensit
specif
hsv
hsv
greater
genit
swab
luminex
ari
hsv
assay
fda
approv
octob
moder
complex
pcr
assay
detect
discrimin
hsv
ari
system
hold
sampl
time
two
magazin
cutan
mucocutan
sampl
inocul
cassett
load
magazin
magazin
hold
six
cassett
need
full
load
instrument
user
start
assay
addit
cassett
ad
magazin
run
magazin
load
start
time
packag
insert
list
sensit
cutan
mucocutan
lesion
respect
sensit
cutan
mucocutan
lesion
respect
specif
cutan
mucocutan
lesion
respect
specif
cutan
mucocutan
lesion
respect
refer
method
elvi
hsvid
type
test
system
peerreview
public
need
verifi
characterist
current
sampletoresult
molecular
assay
syphili
new
techniqu
diagnosi
quantit
hiv
undergo
evalu
perhap
see
becom
mainstream
futur
sampletoresult
molecular
infecti
diseas
assay
perform
except
high
sensit
specif
fast
simpl
perform
requir
resourc
space
personnel
train
limit
accompani
type
test
first
scope
molecular
assay
rang
target
singl
organ
organ
extraordinarili
larg
panel
test
target
numer
organ
filmarray
gastrointestin
panel
lead
shift
provid
think
diagnost
test
eg
larg
multiplex
panel
make
obtain
patient
histori
physic
exam
less
import
need
elucid
inform
one
test
possibl
etiolog
balanc
diagnost
techniqu
challeng
rememb
posit
neg
predict
valu
differ
patient
popul
upmost
import
must
continu
emphas
appropri
interpret
result
test
easi
perform
highli
access
obtain
result
inappropri
patient
clinic
context
often
find
result
current
miss
convent
diagnost
test
may
substanti
difficulti
assess
clinic
implic
result
exampl
possibl
c
difficil
colon
organ
discuss
util
target
treatment
eg
rhinoviru
also
uncertain
organ
influenza
mutat
time
theori
mutat
could
lead
decreas
sensit
assay
time
signific
concern
howev
potenti
need
period
revalid
forbid
would
larg
amount
work
revalid
assay
yearli
also
assay
specif
specimen
sourc
approv
may
limit
util
test
exampl
filmarray
rp
approv
use
nasopharyng
swab
patient
would
benefit
test
lower
respiratori
tract
specimen
bronchioalveolar
lavag
less
pain
specimen
collect
nasal
swab
anoth
limit
molecular
test
inabl
perform
resist
test
isol
surveil
public
health
purpos
addit
platform
aler
filmarray
verigen
coba
liat
run
one
sampl
time
allow
custom
base
need
laboratori
even
small
mediums
lab
may
need
numer
devic
keep
test
volum
prevent
backlog
specimen
current
biggest
area
concern
cost
test
seen
review
mani
studi
demonstr
posit
downstream
effect
test
shorter
length
hospit
stay
lead
substanti
decreas
overal
healthcar
cost
howev
larg
upfront
cost
increas
per
test
cost
challeng
overcom
molecular
infecti
diseas
test
becom
simpl
term
sampletoresult
common
terminolog
result
numer
somewhat
small
chang
ad
substanti
shift
way
molecular
diagnost
perform
addit
improv
lead
broader
use
assay
cost
declin
test
menu
expand
includ
organ
test
may
includ
quantit
result
addit
qualit
result
instrument
becom
smaller
portabl
lead
shift
physic
locat
test
special
molecular
laboratori
microbiolog
lab
gener
core
lab
eventu
direct
patient
test
site
patient
bedsid
within
five
year
certain
see
enorm
growth
poc
molecular
test
perform
licens
personnel
necessarili
laboratori
staff
mean
test
fairli
easili
perform
clinic
urgent
care
pharmaci
emerg
depart
set
order
come
fruition
test
need
faster
less
minut
also
modifi
appeal
nonlab
staff
lab
staff
member
accustom
common
task
precis
pipet
document
qualiti
control
step
need
elimin
autom
use
wide
rang
profession
even
nonprofession
provid
addit
sampletoresult
test
becom
routin
resourcelimit
set
burden
diseas
tend
except
high
poc
test
tuberculosi
alreadi
use
outsid
us
test
hiv
hepat
c
viru
develop
studi
demonstr
sensit
specif
new
test
continu
import
may
overshadow
studi
demonstr
impact
patient
care
longer
good
enough
assay
perform
well
necessari
show
lead
shorter
hospit
length
stay
faster
time
appropri
treatment
elimin
unnecessari
treatment
overal
decreas
healthcar
cost
measur
best
practic
line
idea
person
precis
medicin
grow
area
emphasi
today
practic
health
care
